STEC-HUS, atypical HUS and TTP are all diseases of complement activation

Nature Reviews Nephrology

Volumn 8, Issue 11, 2012, Pages 622-633

  Noris, Marina ^a   Mescia, Federica ^b   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ARC 1905; CCX 168; CDX 1135; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5B; COMPLEMENT FACTOR H; COMPLEMENT INHIBITOR; ECULIZUMAB; FCFD 4514S; IFX 1; JPE 1375; JSM 7717; MONOCLONAL ANTIBODY; MUBODINA; NNC 0151 0000 0000; PADGEM PROTEIN; PEXELIZUMAB; PMX 53; POT 4; RECEPTOR ANTIBODY; RECOMBINANT COMPLEMENT FACTOR H; RECOMBINANT PROTEIN; RITUXIMAB; STEROID; TA 106; TT 30; UNCLASSIFIED DRUG; VINCRISTINE;

ANCA ASSOCIATED VASCULITIS; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT BLOOD LEVEL; COMPLEMENT DEPOSITION; COMPLEMENT SYSTEM; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; GENE MUTATION; GENETIC PREDISPOSITION; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFLAMMATION; MICROTHROMBUS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; POSITIVE FEEDBACK; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SHIGA TOXIN PRODUCING ESCHERICHIA COLI HEMOLYTIC UREMIC SYNDROME; SHIGA TOXIN PRODUCING ESCHERICHIAL COLI HEMOLYTIC UREMIC SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; UPREGULATION;

ADAM PROTEINS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT ACTIVATION; COMPLEMENT C3B; ENDOTHELIUM, VASCULAR; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOLOGIC FACTORS; PLATELET ACTIVATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84867997580     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.195     Document Type: Review

References (132)

1. Ruggenenti, P., Noris, M. & Remuzzi, G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 60, 831-846 (2001
2. Remuzzi, G. et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 100, 778-785 (2002
3. Remuzzi, G. HUS and TTP: variable expression of a single entity. Kidney Int. 32, 292-308 (1987
4. Tarr, P. I., Gordon, C. A. & Chandler, W. L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365, 1073-1086 (2005
5. Noris, M. & Remuzzi, G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361, 1676-1687 (2009
6. Kavanagh, D. & Goodship, T. Genetics and complement in atypical HUS. Pediatr. Nephrol. 25, 2431-2442 (2010
7. Furlan, M. et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N. Engl. J. Med. 339, 1578-1584 (1998
8. Tsai, H. M. & Lian, E. C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N. Engl. J. Med. 339, 1585-1594 (1998
9. Tsai, H. M. Pathophysiology of thrombotic thrombocytopenic purpura. Int. J. Hematol. 91, 1-19 (2010
10. Tsai, H. M. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J. Thromb. Haemost. 1, 625-631 (2003
11. Sarma, J. V. & Ward, P. A. The complement system. Cell Tissue Res. 343, 227-235 (2011
12. Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. Complement: A key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785-797 (2010
13. Morigi, M. et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J. Immunol. 187, 172-180 (2011
14. Ikeda, K. et al. C5a induces tissue factor activity on endothelial cells. Thromb. Haemost. 77, 394-398 (1997
15. Tedesco, F. et al. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J. Exp. Med. 185, 1619-1627 (1997
16. Platt, J. L. et al. Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J. Exp. Med. 171, 1363-1368 (1990
17. Saadi, S. & Platt, J. L. Transient perturbation of endothelial integrity induced by natural antibodies and complement. J. Exp. Med. 181, 21-31 (1995
18. Kilgore, K. S., Ward, P. A. & Warren, J. S. Neutrophil adhesion to human endothelial cells is induced by the membrane attack complex: The roles of P-selectin and platelet activating factor. Inflammation 22, 583-598 (1998
19. Albrecht, E. A. et al. C5a-induced gene expression in human umbilical vein endothelial cells. Am. J. Pathol. 164, 849-859 (2004
20. Dobrina, A. et al. Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood 99, 185-192 (2002
21. Niculescu, F. & Rus, H. Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells. Immunol. Res. 24, 191-199 (2001
22. Klos, A. et al. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46, 2753-2766 (2009
23. Polley, M. J. & Nachman, R. The human complement system in thrombin-mediated platelet function. J. Exp. Med. 147, 1713-1726 (1978
24. Polley, M. J. & Nachman, R. L. Human platelet activation by C3a and C3a des-Arg. J. Exp. Med. 158, 603-615 (1983
25. Wiedmer, T. & Sims, P. J. Effect of complement proteins C5b-9 on blood platelets. Evidence for reversible depolarization of membrane potential. J. Biol. Chem. 260, 8014-8019 (1985
26. Ando, B., Wiedmer, T., Hamilton, K. K. & Sims, P. J. Complement proteins C5b-9 initiate secretion of platelet storage granules without increased binding of fibrinogen or von Willebrand factor to newly expressed cell surface GPIIb-IIIa. J. Biol. Chem. 263, 11907-11914 (1988
27. Wiedmer, T., Esmon, C. T. & Sims, P. J. On the mechanism by which complement proteins C5b-9 increase platelet prothrombinase activity. J. Biol. Chem. 261, 14587-14592 (1986
28. Sims, P. J., Faioni, E. M., Wiedmer, T. & Shattil, S. J. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J. Biol. Chem. 263, 18205-18212 (1988
29. Ståhl, A. L. et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 111, 5307-5315 (2008
30. Gushiken, F. C., Han, H., Li, J., Rumbaut, R. E. & Afshar-Kharghan, V. Abnormal platelet function in C3-deficient mice. J. Thromb. Haemost. 7, 865-870 (2009
31. Høgåsen, A. K., Würzner, R., Abrahamsen, T. G. & Dierich, M. P. Human polymorphonuclear leukocytes store large amounts of terminal complement components C7 and C6, which may be released on stimulation. J. Immunol. 154, 4734-4740 (1995
32. Botto, M., Lissandrini, D., Sorio, C. & Walport, M. J. Biosynthesis and secretion of complement component (C3) by activated human polymorphonuclear leukocytes. J. Immunol. 149, 1348-1355 (1992
33. Vogt, W. Complement activation by myeloperoxidase products released from stimulated human polymorphonuclear leukocytes. Immunobiology 195, 334-346 (1996
34. Camous, L. et al. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 117, 1340-1349 (2011
35. Peerschke, E. I., Yin, W. & Ghebrehiwet, B. Complement activation on platelets: Implications for vascular inflammation and thrombosis. Mol. Immunol. 47, 2170-2175 (2010
36. Amara, U. et al. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 185, 5628-5636 (2010
37. Frank, C. et al. for the HUS Investigation Team. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N. Engl. J. Med. 365, 1771-1780 (2011
38. Rasko, D. A. et al. Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N. Engl. J. Med. 365, 709-717 (2011
39. Obrig, T. G. et al. Endothelial heterogeneity in Shiga toxin receptors and responses. J. Biol. Chem. 268, 15484-15488 (1993
40. Johannes, L. & Römer, W. Shiga toxins - from cell biology to biomedical applications. Nat. Rev. Microbiol. 8, 105-116 (2010
41. Zoja, C. et al. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-κB dependent up-regulation of IL-8 and MCP-1. Kidney Int. 62, 846-856 (2002
42. Petruzziello-Pellegrini, T. N. et al. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-Associated hemolytic uremic syndrome in humans and mice. J. Clin. Invest. 122, 759-776 (2012
43. Morigi, M. et al. Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. Blood 86, 4553-4558 (1995
44. Morigi, M. et al. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood 98, 1828-1835 (2001
45. Nestoridi, E., Tsukurov, O., Kushak, R. I., Ingelfinger, J. R. & Grabowski, E. F. Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: Implications for the pathophysiology of hemolytic uremic syndrome. J. Thromb. Haemost. 3, 752-762 (2005
46. Karpman, D. et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood 97, 3100-3108 (2001
47. van Setten, P. A., Monnens, L. A., Verstraten, R. G., van den Heuvel, L. P. & van Hinsbergh, V. W. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood 88, 174-183 (1996
48. Cameron, J. S. & Vick, R. Letter: Plasma-C3 in haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura. Lancet 2, 975 (1973
49. Kaplan, B. S., Thomson, P. D. & MacNab, G. M. Letter: Serum-complement levels in haemolytic-uraemic syndrome. Lancet 2, 1505-1506 (1973
50. Monnens, L., Hendrickx, G., van Wieringen, P. & van Munster, P. Letter: Serum-complement levels in haemolytic-uraemic syndrome. Lancet 2, 294 (1974
51. Robson, W. L., Leung, A. K., Fick, G. H. & McKenna, A. I. Hypocomplementemia and leukocytosis in diarrhea-Associated hemolytic uremic syndrome. Nephron 62, 296-299 (1992
52. Lapeyraque, A. L. et al. Eculizumab in severe Shiga-toxin-associated HUS. N. Engl. J. Med. 364, 2561-2563 (2011
53. Monnens, L., Molenaar, J., Lambert, P. H., Proesmans, W. & van Munster, P. The complement system in hemolytic-uremic syndrome in childhood. Clin. Nephrol. 13, 168-171 (1980
54. Thurman, J. M. et al. Alternative pathway of complement in children with diarrhea-Associated hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 4, 1920-1924 (2009
55. Ståhl, A. L., Sartz, L. & Karpman, D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117, 5503-5513 (2011
56. Del Conde, I., Crúz, M. A., Zhang, H., López, J. A. & Afshar-Kharghan, V. Platelet activation leads to activation and propagation of the complement system. J. Exp. Med. 201, 871-879 (2005
57. Orth, D. et al. Shiga toxin activates complement and binds factor H: Evidence for an active role of complement in hemolytic uremic syndrome. J. Immunol. 182, 6394-6400 (2009
58. Karmali, M. A. et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 151, 775-782 (1985
59. Caprioli, A. et al. Hemolytic-uremic syndrome and Vero cytotoxin-producing Escherichia coli infection in Italy. The HUS Italian Study Group. J. Infect. Dis. 166, 154-158 (1992
60. Stühlinger, W., Kourilsky, O., Kanfer, A. & Sraer, J. D. Letter: Haemolytic-uraemic syndrome: Evidence for intravascular C3 activation. Lancet 2, 788-789 (1974
61. Carreras, L. et al. Familial hypocomplementemic hemolytic uremic syndrome with HLA-A3,B7 haplotype. JAMA 245, 602-604 (1981
62. Warwicker, P. et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 53, 836-844 (1998
63. Noris, M., Bresin, E., Mele, C., Remuzzi, G. & Caprioli, J. Atypical hemolytic-uremic syndrome. NCBI Bookshelf [online], http://www.ncbi.nlm.nih.gov/ books/NBK1367/?report=printable (2011
64. Neumann, H. P. et al. Haemolytic uraemic syndrome and mutations of the factor H gene: A registry-based study of German speaking countries. J. Med. Genet. 40, 676-681 (2003
65. Caprioli, J. et al. Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108, 1267-1279 (2006
66. Richards, A. et al. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am. J. Hum. Genet. 68, 485-490 (2001
67. Noris, M. et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 362, 1542-1547 (2003
68. Richards, A. et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc. Natl Acad. Sci. USA 100, 12966-12971 (2003
69. Fremeaux-Bacchi, V. et al. Complement factor I: A susceptibility gene for atypical haemolytic uraemic syndrome. J. Med. Genet. 41, e84 (2004
70. Kavanagh, D. et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16, 2150-2155 (2005
71. Bienaime, F. et al. Mutations in components of complement influence the outcome of factor I-Associated atypical hemolytic uremic syndrome. Kidney Int. 77, 339-349 (2010
72. Delvaeye, M. et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361, 345-357 (2009
73. Frémeaux-Bacchi, V. et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112, 4948-4952 (2008
74. Goicoechea de Jorge, E. et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc. Natl Acad. Sci. USA 104, 240-245 (2007
75. Dragon-Durey, M. A. et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16, 555-563 (2005
76. Dragon-Durey, M. A. et al. Clinical features of anti-factor H autoantibody-Associated hemolytic uremic syndrome. J. Am. Soc. Nephrol. 21, 2180-2187 (2010
77. Ferreira, V. P. et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J. Immunol. 182, 7009-7018 (2009
78. Manuelian, T. et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J. Clin. Invest. 111, 1181-1190 (2003
79. Heinen, S. et al. Hemolytic uremic syndrome: A factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells. J. Am. Soc. Nephrol. 18, 506-514 (2007
80. Strobel, S. et al. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol. Dial. Transplant. 25, 136-144 (2010
81. Józsi, M. et al. Anti factor H autoantibodies block C-Terminal recognition function of factor H in hemolytic uremic syndrome. Blood 110, 1516-1518 (2007
82. Fremeaux-Bacchi, V. et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 17, 2017-2025 (2006
83. Kavanagh, D. et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol. Immunol. 45, 95-105 (2008
84. Roumenina, L. T. et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 114, 2837-2845 (2009
85. Noris, M. et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J. Am. Soc. Nephrol. 10, 281-293 (1999
86. Landau, D. et al. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J. Pediatr. 138, 412-417 (2001
87. Ohali, M. et al. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatr. Nephrol. 12, 619-624 (1998
88. Zachwieja, J., Strzykala, K., Golda, W. & Maciejewski, J. Familial, recurrent haemolytic-uraemic syndrome with hypocomplementaemia. Pediatr. Nephrol. 6, 221-222 (1992
89. Vaziri-Sani, F. et al. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int. 69, 981-988 (2006
90. Richards, A. Glomerular endothelial microvascular heterogeneity and response to cytokines predispose to development of atypical HUS [abstract]. Mol. Immunol. 48, 1732 (2011
91. Noris, M. et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 5, 1844-1859 (2010
92. Moore, I. et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115, 379-387 (2010
93. Esparza-Gordillo, J. et al. Insights into hemolytic uremic syndrome: Segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol. Immunol. 43, 1769-1775 (2006
94. Esparza-Gordillo, J. et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum. Mol. Genet. 14, 703-712 (2005
95. Pickering, M. C. et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J. Exp. Med. 204, 1249-1256 (2007
96. Fakhouri, F. et al. Pregnancy-Associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J. Am. Soc. Nephrol. 21, 859-867 (2010
97. Galbusera, M. et al. In patients with atypical hemolytic uremic syndrome C5 activation causes loss of endothelial thromboresistance [abstract]. Mol. Immunol. 48, 1680 (2011
98. Fang, C. J. et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 111, 624-632 (2008
99. Sadler, J. E. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 112, 11-18 (2008
100. Plaimauer, B. et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 100, 3626-3632 (2002
101. Levy, G. G. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413, 488-494 (2001
102. Donadelli, R. et al. In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb. Haemost. 96, 454-464 (2006
103. Vesely, S. K. et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102, 60-68 (2003
104. Veyradier, A., Obert, B., Houllier, A., Meyer, D. & Girma, J. P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: A study of 111 cases. Blood 98, 1765-1772 (2001
105. Weisenburger, D. D., O'Conner, M. L. & Hart, M. N. Thrombotic thrombocytopenic purpura with C3 vascular deposits: Report of a case. Am. J. Clin. Pathol. 67, 61-63 (1977
106. Wright, J. F. et al. Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura. Br. J. Haematol. 107, 546-555 (1999
107. Ruiz-Torres, M. P. et al. Complement activation: The missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb. Haemost. 93, 443-452 (2005
108. Réti, M. et al. Complement activation in thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 10, 791-798 (2012
109. Chapin, J., Weksler, B., Magro, C. & Laurence, J. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br. J. Haematol. 157, 772-774 (2012
110. Huber-Lang, M. et al. Generation of C5a in the absence of C3: A new complement activation pathway. Nat. Med. 12, 682-687 (2006
111. Dubois, E. A. & Cohen, A. F. Eculizumab. Br. J. Clin. Pharmacol. 68, 318-319 (2009
112. Stahl, R. Eculizumab experience in HUS. Presented at the 2011 American Society of Nephrology Kidney Week
113. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01410916?term=NCT01410916&rank=1 (2012
114. Kielstein, J. et al. Best supportive care and therapeutic plasma exchange [abstract SAP179]. Nephrol. Dial. Transplant. 27 (SUPPL. 2), ii373-ii374 (2012
115. Gruppo, R. A. & Rother, R. P. Eculizumab for congenital atypical hemolytic-uremic syndrome. N. Engl. J. Med. 360, 544-546 (2009
116. Ariceta, G., Arrizabalaga, B., Aguirre, M., Morteruel, E. & Lopez-Trascasa, M. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am. J. Kidney Dis. 59, 707-710 (2012
117. Nürnberger, J. et al. Eculizumab for atypical hemolytic-uremic syndrome. N. Engl. J. Med. 360, 542-544 (2009
118. Châtelet, V. et al. Eculizumab: Safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: Case report. Transplant. Proc. 42, 4353-4355 (2010
119. Zimmerhackl, L. B. et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 362, 1746-1748 (2010
120. Weitz, M., Amon, O., Bassler, D., Koenigsrainer, A. & Nadalin, S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr. Nephrol. 26, 1325-1329 (2011
121. Licht, C. et al. Ph II study of eculizumab (ECU) in patients (PTS) with atypical hemolytic uremic syndrome (aHUS) receiving chronic plasma exchange/infusion (PE/PI) [abstract TH-PO366]. J. Am. Soc. Nephrol. 22, 197A (2011
122. Greenbaum, L. A. et al. Continued improvements in renal function with sustained eculizumab (ECU) in patients (PTS) with atypical hemolytic uremic syndrome (aHUS) resistant to plasma exchange/infusion (PE/PI) [abstract TH-PO367]. J. Am. Soc. Nephrol. 22, 197A (2011
123. Woodruff, T. M., Nandakumar, K. S. & Tedesco, F. Inhibiting the C5-C5a receptor axis. Mol. Immunol. 48, 1631-1642 (2011
124. Troutbeck, R., Al-Qureshi, S. & Guymer, R. H. Therapeutic targeting of the complement system in age-related macular degeneration: A review. Clin. Experiment. Ophthalmol. 40, 18-26 (2012
125. Risitano, A. M. et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 113, 4094-4100 (2009
126. Noris, M. & Remuzzi, G. Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. Semin. Nephrol. 30, 395-408 (2010
127. Salmon, J. E. et al. Mutations in complement regulatory proteins predispose to preeclampsia: A genetic analysis of the PROMISSE cohort. Plos Med. 8, e1001013 (2011
128. Le Quintrec, M. et al. Complement mutation-Associated de novo thrombotic microangiopathy following kidney transplantation. Am. J. Transplant. 8, 1694-1701 (2008
129. Lonze, B. E., Singer, A. L. & Montgomery, R. A. Eculizumab and renal transplantation in a patient with CAPS. N. Engl. J. Med. 362, 1744-1745 (2010
130. Lazar, H. L. et al. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 110, II274-II279 (2004
131. Testa, L. et al. Pexelizumab in ischemic heart disease: A systematic review and meta-Analysis on 15,196 patients. J. Thorac. Cardiovasc. Surg. 136, 884-893 (2008
132. Vergunst, C. E. et al. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology (Oxford) 46, 1773-1778 (2007